指南与共识前列腺癌男科与性医学

年轻与年长男性在睾酮治疗前接受前列腺特异性抗原筛查趋势的差异:指南变迁背景下的分析

Divergent Trends in Prostate-specific Antigen Screening Prior to Testosterone Therapy in Younger vs Older Men Amidst Shifting Guidelines.
指南 / 共识 · Urology · 2025-12-22

该回顾性队列研究基于TriNetX网络数据,纳入2009至2022年间接受睾酮替代治疗的40-69岁男性,评估治疗前1年内前列腺特异性抗原(PSA)筛查率随年龄、种族和指南时期的变化。结果显示总体筛查率低(40-54岁12.2%,55-69岁18.6%),年轻组筛查率未随时间改善,而年长组在2013-2022年显著上升;黑人年轻男性筛查几率高于白人。结论强调需加强教育以改善治疗前前列腺癌风险评估。

要点

  • 睾酮治疗前PSA筛查率总体偏低,40-54岁仅12.2%,55-69岁18.6%。
  • 年轻组(40-54岁)筛查率在两个指南时期无差异(11.5% vs 12.2%)。
  • 年长组(55-69岁)筛查率在2013-2022年显著上升(16.8% vs 19.5%)。

核心结论

  • 尽管有长期推荐,睾酮治疗前PSA筛查率仍低,尤其是年轻和高风险男性。
  • 指南变迁可能影响筛查趋势,需针对性教育改善治疗前前列腺癌风险评估。

研究设计与样本

  • 回顾性队列研究,使用TriNetX研究网络数据,纳入2009-2022年接受睾酮替代治疗的40-69岁男性,共74,463人。
  • 按年龄、种族、民族和临床特征进行1:1倾向性评分匹配后分析。

主要发现

  • 总体中,40-54岁男性治疗前1年内PSA筛查率为12.2%,55-69岁为18.6%。
  • 40-54岁男性筛查率在两个指南时期无差异(11.5% vs 12.2%)。
  • 55-69岁男性筛查率在2013-2022年显著高于2009-2012年(16.8% vs 19.5%)。
  • 总体筛查率无种族差异,但40-54岁黑人男性筛查几率高于白人男性。

临床怎么用

  • 泌尿外科医生在启动睾酮治疗前应常规评估前列腺癌风险并考虑PSA筛查。
  • 对年轻男性(40-54岁)及高风险人群需加强教育,提高治疗前PSA筛查率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess whether prostate-specific antigen (PSA) testing rates prior to testosterone replacement therapy (TTh) differed by age (40-54 vs 55-69), race, and guideline era (2009-2012 vs 2013-2022). METHODS: We performed a retrospective cohort study using the TriNetX Research Network, including men aged 40-69 who received TTh for hypogonadism between 2009 and 2022. The primary outcome was PSA screening within 1 year before TTh. Analyses were performed after 1:1 propensity score matching by age, race, ethnicity, and clinical characteristics. RESULTS: Among 74,463 men, 12.2% of those aged 40-54 and 18.6% of those aged 55-69 were screened within 1 year of TTh initiation. For men aged 40-54, rates did not differ across eras (11.5% vs 12.2%). In men aged 55-69, screening increased significantly in 2013-2022 (16.8% vs 19.5%). Overall pre-TTh screening rates did not differ by race; however, Black men aged 40-54 had higher odds of screening than White men. CONCLUSION: Despite longstanding recommendations, PSA screening prior to TTh remains low, particularly in younger and high-risk men. Shifting guidelines may contribute. These findings underscore the need for education and targeted strategies to improve prostate cancer risk assessment before TTh.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. DeMasi M, Evans A, Syphan T, et al. Divergent Trends in Prostate-specific Antigen Screening Prior to Testosterone Therapy in Younger vs Older Men Amidst Shifting Guidelines. Urology. 2025. PMID: 41443475. doi:10.1016/j.urology.2025.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。